RU2009100878A - Эпоксидные ингибиторы цистеинпротеаз - Google Patents
Эпоксидные ингибиторы цистеинпротеаз Download PDFInfo
- Publication number
- RU2009100878A RU2009100878A RU2009100878/21A RU2009100878A RU2009100878A RU 2009100878 A RU2009100878 A RU 2009100878A RU 2009100878/21 A RU2009100878/21 A RU 2009100878/21A RU 2009100878 A RU2009100878 A RU 2009100878A RU 2009100878 A RU2009100878 A RU 2009100878A
- Authority
- RU
- Russia
- Prior art keywords
- group
- infection
- compound
- alkyl
- compound according
- Prior art date
Links
- 239000004593 Epoxy Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 54
- -1 aralkenyl Chemical group 0.000 claims abstract 53
- 125000000217 alkyl group Chemical group 0.000 claims abstract 23
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract 23
- 125000003118 aryl group Chemical group 0.000 claims abstract 23
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 23
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 18
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 18
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims abstract 18
- 125000003342 alkenyl group Chemical group 0.000 claims abstract 12
- 125000000304 alkynyl group Chemical group 0.000 claims abstract 12
- 125000000392 cycloalkenyl group Chemical group 0.000 claims abstract 12
- 125000005842 heteroatom Chemical group 0.000 claims abstract 12
- 125000004449 heterocyclylalkenyl group Chemical group 0.000 claims abstract 12
- 229930194542 Keto Chemical group 0.000 claims abstract 11
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 11
- 125000004104 aryloxy group Chemical group 0.000 claims abstract 11
- 229910052799 carbon Inorganic materials 0.000 claims abstract 11
- 125000004181 carboxyalkyl group Chemical group 0.000 claims abstract 11
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims abstract 11
- 125000000468 ketone group Chemical group 0.000 claims abstract 11
- 125000000732 arylene group Chemical group 0.000 claims abstract 10
- 125000002993 cycloalkylene group Chemical group 0.000 claims abstract 10
- 125000005549 heteroarylene group Chemical group 0.000 claims abstract 10
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims abstract 10
- 125000004429 atom Chemical group 0.000 claims abstract 9
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 9
- 125000004122 cyclic group Chemical group 0.000 claims abstract 9
- 125000004475 heteroaralkyl group Chemical group 0.000 claims abstract 7
- 125000003282 alkyl amino group Chemical group 0.000 claims abstract 6
- 125000000000 cycloalkoxy group Chemical group 0.000 claims abstract 6
- 125000004404 heteroalkyl group Chemical group 0.000 claims abstract 6
- 239000000651 prodrug Substances 0.000 claims abstract 6
- 229940002612 prodrug Drugs 0.000 claims abstract 6
- 150000001336 alkenes Chemical class 0.000 claims abstract 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 5
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims 28
- 208000015181 infectious disease Diseases 0.000 claims 22
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 20
- 125000001424 substituent group Chemical group 0.000 claims 15
- 235000013877 carbamide Nutrition 0.000 claims 10
- 239000004202 carbamide Substances 0.000 claims 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims 10
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 10
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 claims 10
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims 9
- 239000004365 Protease Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 5
- 125000002252 acyl group Chemical group 0.000 claims 5
- 125000005236 alkanoylamino group Chemical group 0.000 claims 5
- 125000005239 aroylamino group Chemical group 0.000 claims 5
- ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical compound OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 235000001014 amino acid Nutrition 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 108010005843 Cysteine Proteases Proteins 0.000 claims 3
- 102000005927 Cysteine Proteases Human genes 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 108090000526 Papain Proteins 0.000 claims 3
- 108091005804 Peptidases Proteins 0.000 claims 3
- 102000035195 Peptidases Human genes 0.000 claims 3
- 206010035660 Pneumocystis Infections Diseases 0.000 claims 3
- 201000006592 giardiasis Diseases 0.000 claims 3
- 201000006938 muscular dystrophy Diseases 0.000 claims 3
- 235000019834 papain Nutrition 0.000 claims 3
- 229940055729 papain Drugs 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 102000005600 Cathepsins Human genes 0.000 claims 2
- 108010084457 Cathepsins Proteins 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000004554 Leishmaniasis Diseases 0.000 claims 2
- 208000019693 Lung disease Diseases 0.000 claims 2
- 208000030852 Parasitic disease Diseases 0.000 claims 2
- 208000025598 Pneumocystis infectious disease Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010044708 Trypanosomal infections Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 206010047505 Visceral leishmaniasis Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 230000002134 immunopathologic effect Effects 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 230000000750 progressive effect Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 229940124530 sulfonamide Drugs 0.000 claims 2
- 230000007838 tissue remodeling Effects 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010001935 American trypanosomiasis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000010392 Bone Fractures Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000001528 Coronaviridae Infections Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 241001464851 Entamoeba invadens Species 0.000 claims 1
- 208000010489 Entamoebiasis Diseases 0.000 claims 1
- 208000037147 Hypercalcaemia Diseases 0.000 claims 1
- 241000222724 Leishmania amazonensis Species 0.000 claims 1
- 241000222727 Leishmania donovani Species 0.000 claims 1
- 241000222697 Leishmania infantum Species 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 244000020186 Nymphaea lutea Species 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 208000003076 Osteolysis Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000027868 Paget disease Diseases 0.000 claims 1
- 240000009188 Phyllostachys vivax Species 0.000 claims 1
- 241000223960 Plasmodium falciparum Species 0.000 claims 1
- 241000223821 Plasmodium malariae Species 0.000 claims 1
- 206010035501 Plasmodium malariae infection Diseases 0.000 claims 1
- 241001505293 Plasmodium ovale Species 0.000 claims 1
- 206010035502 Plasmodium ovale infection Diseases 0.000 claims 1
- 206010073756 Pneumocystis jirovecii infection Diseases 0.000 claims 1
- 201000005485 Toxoplasmosis Diseases 0.000 claims 1
- 241000223109 Trypanosoma cruzi Species 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000148 hypercalcaemia Effects 0.000 claims 1
- 208000030915 hypercalcemia disease Diseases 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000029791 lytic metastatic bone lesion Diseases 0.000 claims 1
- 208000027202 mammary Paget disease Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000000626 mucocutaneous leishmaniasis Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000011164 ossification Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 0 CC(*)C(*NC)=O Chemical compound CC(*)C(*NC)=O 0.000 description 2
- NKWRRUKHBWTRPY-UHFFFAOYSA-N CCc(cc1[N+]([O-])=O)ccc1O Chemical compound CCc(cc1[N+]([O-])=O)ccc1O NKWRRUKHBWTRPY-UHFFFAOYSA-N 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/04—Compounds containing oxirane rings containing only hydrogen and carbon atoms in addition to the ring oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/48—Compounds containing oxirane rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81363906P | 2006-06-13 | 2006-06-13 | |
| US60/813,639 | 2006-06-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2009100878A true RU2009100878A (ru) | 2010-07-20 |
Family
ID=39269056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009100878/21A RU2009100878A (ru) | 2006-06-13 | 2007-06-13 | Эпоксидные ингибиторы цистеинпротеаз |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8673904B2 (enExample) |
| EP (1) | EP2029135A4 (enExample) |
| JP (1) | JP2010500962A (enExample) |
| KR (1) | KR20090029725A (enExample) |
| CN (1) | CN101808634A (enExample) |
| AU (1) | AU2007305138A1 (enExample) |
| BR (1) | BRPI0712868A2 (enExample) |
| CA (1) | CA2655139A1 (enExample) |
| IL (1) | IL195782A0 (enExample) |
| RU (1) | RU2009100878A (enExample) |
| WO (1) | WO2008042480A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2921486B1 (en) | 2009-08-07 | 2017-09-27 | American Life Science Pharmaceuticals, Inc. | Compositions and methods for treating beta-amyloid related diseases |
| US9345789B2 (en) | 2009-12-18 | 2016-05-24 | The Board Of Trustees Of The Leland Stanford Junior University | Specific inhibitors and active site probes for legumain |
| US20140170653A1 (en) | 2011-04-15 | 2014-06-19 | Life Technologies Corporation | Chemical ligation |
| US9403843B2 (en) | 2012-02-01 | 2016-08-02 | The Trustees Of Columbia University In The City Of New York | Cysteine protease inhibitors and uses thereof |
| CN104211666B (zh) * | 2013-05-31 | 2017-11-14 | 中国人民解放军军事医学科学院毒物药物研究所 | 2,3‑环氧丁二酰胺类化合物、其制备方法和用途 |
| CN107151236B (zh) * | 2016-03-03 | 2021-04-30 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种2,3-环氧丁二酰衍生物及其制备方法和用途 |
| EP4324460A3 (en) | 2017-09-15 | 2024-04-24 | Dyve Biosciences, Inc. | Sodium bicarbonate for use in the treatment of gout and related disorders |
| US20190134219A1 (en) * | 2017-09-15 | 2019-05-09 | Ampersand Biopharmaceuticals, Inc. | Inhibition of spontaneous metastasis via protein inhibitors of cysteine proteases |
| CN110241438A (zh) * | 2018-03-08 | 2019-09-17 | 天津大学 | 泡沫铜担载钯铜合金纳米笼催化剂及其制备方法 |
| US11905249B2 (en) | 2021-01-25 | 2024-02-20 | Jackson State University | Covalent inhibitors of equine encephalitis virus |
| KR20230165715A (ko) | 2022-05-27 | 2023-12-05 | 서울대학교산학협력단 | 기생충 감염증의 예방 또는 치료용 약학 조성물 |
| AU2024230810A1 (en) * | 2023-03-02 | 2025-09-04 | Kyoto University | Radioactive metal-labeled antibody, radioactive pharmaceutical, and compound |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1469797A (en) | 1974-11-07 | 1977-04-06 | Pfizer Ltd | Antibacterial cephalosporin derivatives |
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| JPS55115878A (en) * | 1979-02-27 | 1980-09-06 | Taisho Pharmaceut Co Ltd | Epoxysuccinic acid derivative |
| JPS55153778A (en) * | 1979-05-17 | 1980-11-29 | Taisho Pharmaceut Co Ltd | Epoxysuccinylamino acid derivative |
| JPS57169478A (en) | 1981-04-10 | 1982-10-19 | Nippon Chemiphar Co Ltd | Piperazine derivative |
| JPS6276A (ja) | 1985-03-26 | 1987-01-06 | Toyo Jozo Co Ltd | 酵素阻害性新規物質 |
| JP2808877B2 (ja) | 1990-09-29 | 1998-10-08 | 大正製薬株式会社 | エポキシスクシナム酸誘導体およびその中間体 |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| US5556853A (en) | 1993-10-29 | 1996-09-17 | Takeda Chemical Industries, Ltd. | Epoxysuccinic acid derivatives |
| JPH08104683A (ja) * | 1993-10-29 | 1996-04-23 | Takeda Chem Ind Ltd | エポキシコハク酸誘導体 |
| JPH08104684A (ja) * | 1994-05-31 | 1996-04-23 | Takeda Chem Ind Ltd | エポキシコハク酸関連化合物 |
| CA2190151A1 (en) | 1994-05-31 | 1995-12-07 | Shigetoshi Tsubotani | Epoxysuccinic acid derivatives, their production and use |
| AU697565B2 (en) * | 1995-12-12 | 1998-10-08 | Taiho Pharmaceutical Co., Ltd. | Epoxysuccinamide derivative or salt thereof and medicine comprising the same |
| EP0921122B1 (en) * | 1997-04-18 | 2003-05-21 | Taiho Pharmaceutical Company, Limited | Epoxysuccinamide derivatives or salts thereof |
| JPH11263783A (ja) * | 1998-01-09 | 1999-09-28 | Taisho Pharmaceut Co Ltd | エポキシスクシナム酸誘導体 |
| AU2483599A (en) | 1998-01-29 | 1999-08-16 | Sepracor, Inc. | Pharmaceutical uses of optically pure (-)-bupropion |
| AU2002232681A1 (en) | 2000-11-10 | 2002-05-21 | The Regents Of The Univeristy Of California | Activity-dependent cysteine protease profiling reagent |
| US7247684B2 (en) * | 2001-09-12 | 2007-07-24 | Dow Global Technologies Inc. | Network polymers comprising epoxy-terminated esters |
| US20030212003A1 (en) | 2002-02-14 | 2003-11-13 | Hermann Lubbert | Cathepsin Y for the development of a medicament for the treatment of pain |
| US20060154325A1 (en) * | 2005-01-10 | 2006-07-13 | Matthew Bogyo | Synthesis of epoxide based inhibitors of cysteine proteases |
-
2007
- 2007-06-13 AU AU2007305138A patent/AU2007305138A1/en not_active Abandoned
- 2007-06-13 BR BRPI0712868-1A patent/BRPI0712868A2/pt not_active IP Right Cessation
- 2007-06-13 JP JP2009515635A patent/JP2010500962A/ja active Pending
- 2007-06-13 WO PCT/US2007/071145 patent/WO2008042480A2/en not_active Ceased
- 2007-06-13 CN CN200780029699A patent/CN101808634A/zh active Pending
- 2007-06-13 RU RU2009100878/21A patent/RU2009100878A/ru not_active Application Discontinuation
- 2007-06-13 US US11/762,735 patent/US8673904B2/en not_active Expired - Fee Related
- 2007-06-13 EP EP07863360A patent/EP2029135A4/en not_active Withdrawn
- 2007-06-13 CA CA002655139A patent/CA2655139A1/en not_active Abandoned
- 2007-06-13 KR KR1020087030795A patent/KR20090029725A/ko not_active Withdrawn
-
2008
- 2008-12-08 IL IL195782A patent/IL195782A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2029135A4 (en) | 2011-08-17 |
| BRPI0712868A2 (pt) | 2013-05-07 |
| KR20090029725A (ko) | 2009-03-23 |
| EP2029135A2 (en) | 2009-03-04 |
| WO2008042480A2 (en) | 2008-04-10 |
| JP2010500962A (ja) | 2010-01-14 |
| WO2008042480A3 (en) | 2008-08-14 |
| US20080176841A1 (en) | 2008-07-24 |
| AU2007305138A1 (en) | 2008-04-10 |
| IL195782A0 (en) | 2009-09-01 |
| US8673904B2 (en) | 2014-03-18 |
| CA2655139A1 (en) | 2008-04-10 |
| CN101808634A (zh) | 2010-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7703518B2 (ja) | 抗ウイルスプロドラッグ及びその製剤 | |
| JP2014510727A5 (enExample) | ||
| JP2018528261A5 (enExample) | ||
| ES2578905T5 (es) | Inhibidores de proteasa epoxi cetona peptídicos cristalinos y la síntesis de ceto-epóxidos de aminoácidos | |
| EA200900539A1 (ru) | Соединения фенилмочевины (варианты), содержащая их фармацевтическая композиция и способ лечения заболеваний, опосредованных растворимой эпоксидгидролазой (варианты) | |
| JP2019512478A5 (enExample) | ||
| CN103694238B (zh) | No供体型苦参碱衍生物、其制备方法及医药用途 | |
| RU2005119281A (ru) | Диазинопиримидины | |
| WO1997030072B1 (en) | Peptidomimetic inhibitors of cathepsin d and plasmepsins i and ii | |
| EA201490709A1 (ru) | Адъювантное соединение | |
| RU2016120012A (ru) | Ингибиторы рецептора фактора роста фибробластов | |
| JP2016536288A5 (enExample) | ||
| JP2012521363A (ja) | 結晶質トリペプチドエポキシケトンプロテアーゼ阻害剤 | |
| RU2006134020A (ru) | Конденсированные производные пиразола | |
| JPH02174797A (ja) | ペプチド誘導体およびその用途 | |
| KR960700226A (ko) | 탁산유도체의 제조공정과 그 공정의 β-락탐 중간체들 | |
| JP2010500962A5 (enExample) | ||
| RU2007102576A (ru) | Новые индаэолкарбоксамиды и их применение | |
| JP2019504833A5 (enExample) | ||
| RU2011132119A (ru) | Способ получения (+)-1-4-дигидро-7-[(3s,4s)-3-метокси-4-(метиламино)-1-пирролидинил]-4-оксо-1-(2-тиазолил)-1,8-нафтиридин-3-карбоновой кислоты | |
| RU2006103803A (ru) | Соединение, обладающее действием против hcv, и способ его получения | |
| WO2023022231A1 (ja) | ウイルス感染症を処置または予防するための可逆的共有結合阻害物質 | |
| RU2012136457A (ru) | Новые композиции для уменьшения аb 42 синтеза и их применение в лечении болезни альцгеймера (ad) | |
| CN100340557C (zh) | 具有神经镇静活性的齐拉西酮的酰基衍生物 | |
| CN116496189B (zh) | N-酰基次磺酰胺类化合物及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20110901 |